

David A Fox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2505060/publications.pdf>

Version: 2024-02-01

160
papers

11,758
citations

30047

54
h-index

30058

103
g-index

164
all docs

164
docs citations

164
times ranked

13106
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight, 2022, 7, .	2.3	11
2	Soluble CD13 induces inflammatory arthritis by activating the bradykinin receptor B1. Journal of Clinical Investigation, 2022, 132, .	3.9	6
3	IRAK4 inhibition: a promising strategy for treating RA joint inflammation and bone erosion. Cellular and Molecular Immunology, 2021, 18, 2199-2210.	4.8	31
4	Interferon-stimulated GTPases in autoimmune and inflammatory diseases: promising role for the guanylate-binding protein (GBP) family. Rheumatology, 2021, 60, 494-506.	0.9	17
5	CD6 is a target for cancer immunotherapy. JCI Insight, 2021, 6, .	2.3	18
6	Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. Vaccine, 2021, 39, 6111-6116.	1.7	39
7	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. Arthritis Research and Therapy, 2021, 23, 10.	1.6	18
8	CD6-Targeted Antibody-Drug Conjugate As a Potential Therapeutic Agent for T Cell Lymphomas. Blood, 2021, 138, 1193-1193.	0.6	0
9	A CD6-Targeted Antibody-Drug Conjugate As a Potential Therapy for T Cell-Mediated Disorders. Blood, 2021, 138, 3817-3817.	0.6	0
10	Macrophages are the primary effector cells in IL-7-induced arthritis. Cellular and Molecular Immunology, 2020, 17, 728-740.	4.8	45
11	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis and Rheumatology, 2020, 72, 125-136.	2.9	163
12	Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 228-236.	1.6	17
13	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatology, The, 2020, 2, e743-e753.	2.2	34
14	Neutrophil-mediated carbamylation promotes articular damage in rheumatoid arthritis. Science Advances, 2020, 6, .	4.7	49
15	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Annals of the Rheumatic Diseases, 2020, 79, 724-726.	0.5	51
16	Editorial: Immunomodulatory Functions of Fibroblast-like Synoviocytes in Joint Inflammation and Destruction during Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 955.	2.2	5
17	CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders. Journal of Immunology, 2020, 204, 3-11.	0.4	48
18	Attenuation of Murine Collagen-Induced Arthritis by Targeting CD6. Arthritis and Rheumatology, 2020, 72, 1505-1513.	2.9	15

#	ARTICLE	IF	CITATIONS
19	Neutrophil extracellular traps mediate articular cartilage damage and enhance cartilage component immunogenicity in rheumatoid arthritis. <i>JCI Insight</i> , 2020, 5, .	2.3	97
20	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 2451-2464.	3.9	106
21	Real time visualization of cancer cell death, survival and proliferation using fluorochrome-transfected cells in an IncuCyte® imaging system. <i>Journal of Biological Methods</i> , 2020, 7, e133.	1.0	17
22	Angiogenic and Arthritogenic Properties of the Soluble Form of CD13. <i>Journal of Immunology</i> , 2019, 203, 360-369.	0.4	11
23	Citrullinated Inhibitor of <sc>DNA</sc> Binding 1 Is a Novel Autoantigen in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1241-1251.	2.9	4
24	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 92-100.	2.5	28
25	5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4350-4369.	2.9	34
26	Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3695-3702.	3.3	77
27	Absence of complement component 3 does not prevent classical pathway-mediated hemolysis. <i>Blood Advances</i> , 2019, 3, 1808-1814.	2.5	6
28	Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. <i>Arthritis Research and Therapy</i> , 2019, 21, 292.	1.6	31
29	Targeting CD6 for the treatment of experimental autoimmune uveitis. <i>Journal of Autoimmunity</i> , 2018, 90, 84-93.	3.0	27
30	Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy. <i>Journal of Immunology</i> , 2018, 200, 4094-4101.	0.4	42
31	The role of CD6 in autoimmune diseases. <i>Cellular and Molecular Immunology</i> , 2018, 15, 1001-1002.	4.8	3
32	Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 841-854.	2.9	44
33	IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells. <i>Angiogenesis</i> , 2018, 21, 215-228.	3.7	52
34	Response to comment on "Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis". <i>Science Immunology</i> , 2018, 3, .	5.6	5
35	Clinical and experimental evidence for targeting CD6 in immune-based disorders. <i>Autoimmunity Reviews</i> , 2018, 17, 493-503.	2.5	28
36	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. <i>Quality of Life Research</i> , 2018, 27, 755-764.	1.5	52

#	ARTICLE	IF	CITATIONS
37	C3 as a potential target for treating complement-mediated hemolysis. <i>Molecular Immunology</i> , 2018, 102, 183.	1.0	0
38	A unique role for galectin-9 in angiogenesis and inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 31.	1.6	39
39	Transforming growth factor β 2 activated kinase 1: a potential therapeutic target for rheumatic diseases. <i>Rheumatology</i> , 2017, 56, kew301.	0.9	17
40	CD6 as a potential target for treating multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2687-2692.	3.3	70
41	Pharmacokinetic optimization of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1744-1749.	1.0	42
42	DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. <i>Nature Communications</i> , 2017, 8, 14252.	5.8	75
43	Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. <i>Science Immunology</i> , 2017, 2, .	5.6	228
44	Synovial cellular and molecular markers in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 2017, 39, 385-393.	2.8	89
45	The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases. <i>Clinical Immunology</i> , 2017, 175, 10-15.	1.4	52
46	TLRs, future potential therapeutic targets for RA. <i>Autoimmunity Reviews</i> , 2017, 16, 103-113.	2.5	118
47	CD318 is a ligand for CD6. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6912-E6921.	3.3	67
48	Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF- α Inhibition for Cancer and Autoimmune Disease. <i>Cell Chemical Biology</i> , 2017, 24, 1029-1039.e7.	2.5	104
49	Seven-Year Outcomes of the Silicone Arthroplasty in Rheumatoid Arthritis Prospective Cohort Study. <i>Arthritis Care and Research</i> , 2017, 69, 973-981.	1.5	22
50	Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis via Repression of Proangiogenic Factors. <i>Arthritis and Rheumatology</i> , 2016, 68, 2975-2985.	2.9	62
51	Phospholipase D enzymes facilitate IL-17- and TNF- α -induced expression of proinflammatory genes in rheumatoid arthritis synovial fibroblasts (RASf). <i>Immunology Letters</i> , 2016, 174, 9-18.	1.1	33
52	Inflammatory properties of inhibitor of DNA binding 1 secreted by synovial fibroblasts in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 87.	1.6	23
53	Localization, Shedding, Regulation and Function of Aminopeptidase N/CD13 on Fibroblast like Synoviocytes. <i>PLoS ONE</i> , 2016, 11, e0162008.	1.1	18
54	Loss of SH3 Domain-Binding Protein 2 Function Suppresses Bone Destruction in Tumor Necrosis Factor-Driven and Collagen-Induced Arthritis in Mice. <i>Arthritis and Rheumatology</i> , 2015, 67, 656-667.	2.9	48

#	ARTICLE	IF	CITATIONS
55	Patient expectations and long-term outcomes in rheumatoid arthritis patients: results from the SARA (Silicone Arthroplasty in Rheumatoid Arthritis) study. <i>Clinical Rheumatology</i> , 2015, 34, 641-651.	1.0	22
56	The Incidence of Upper and Lower Extremity Surgery for Rheumatoid Arthritis Among Medicare Beneficiaries. <i>Journal of Bone and Joint Surgery - Series A</i> , 2015, 97, 403-410.	1.4	21
57	Killer B Lymphocytes and Their Fas Ligand Positive Exosomes as Inducers of Immune Tolerance. <i>Frontiers in Immunology</i> , 2015, 6, 122.	2.2	38
58	Variation in Rheumatoid Hand and Wrist Surgery among Medicare Beneficiaries: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 429-436.	1.0	25
59	Citrullination: A Specific Target for the Autoimmune Response in Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2015, 195, 5-7.	0.4	18
60	Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 3153-3162.	0.3	23
61	Current and future approaches to the treatment of immunologic diseases: new targets and new therapeutic agents. <i>Translational Research</i> , 2015, 165, 251-254.	2.2	0
62	Expression and Function of Aminopeptidase N/CD13 Produced by Fibroblast-Like Synoviocytes in Rheumatoid Arthritis: Role of CD13 in Chemotaxis of Cytokine-Activated T Cells Independent of Enzymatic Activity. <i>Arthritis and Rheumatology</i> , 2015, 67, 74-85.	2.9	38
63	SH3BP2 Gain-Of-Function Mutation Exacerbates Inflammation and Bone Loss in a Murine Collagen-Induced Arthritis Model. <i>PLoS ONE</i> , 2014, 9, e105518.	1.1	20
64	Human B Cell-Derived Lymphoblastoid Cell Lines Constitutively Produce Fas Ligand and Secrete MHCII+ FasL+ Killer Exosomes. <i>Frontiers in Immunology</i> , 2014, 5, 144.	2.2	69
65	Noxa in rheumatic diseases: present understanding and future impact. <i>Rheumatology</i> , 2014, 53, 1539-1546.	0.9	7
66	T cell subsets and their role in the pathogenesis of rheumatic disease. <i>Current Opinion in Rheumatology</i> , 2014, 26, 204-210.	2.0	85
67	Targeting the Myofibroblast Genetic Switch: Inhibitors of Myocardin-Related Transcription Factor/Serum Response Factor-Regulated Gene Transcription Prevent Fibrosis in a Murine Model of Skin Injury. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 349, 480-486.	1.3	92
68	Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. <i>Blood</i> , 2014, 123, 786-793.	0.6	94
69	Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts. <i>Arthritis Research and Therapy</i> , 2014, 16, 411.	1.6	20
70	Modulating myofibroblast transition in systemic sclerosis through inhibition of Rho/MRTF regulated transcription (1054.9). <i>FASEB Journal</i> , 2014, 28, 1054.9.	0.2	0
71	Top3 ^{Î²} is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. <i>Nature Neuroscience</i> , 2013, 16, 1238-1247.	7.1	124
72	The roles of IFN-Î³ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. <i>Modern Rheumatology</i> , 2013, 23, 1140-1150.	0.9	27

#	ARTICLE	IF	CITATIONS
73	NETs Are a Source of Citrullinated Autoantigens and Stimulate Inflammatory Responses in Rheumatoid Arthritis. <i>Science Translational Medicine</i> , 2013, 5, 178ra40.	5.8	1,016
74	Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling. <i>Arthritis and Rheumatism</i> , 2013, 65, 618-626.	6.7	48
75	The Effect of Swan Neck and Boutonniere Deformities on the Outcome of Silicone Metacarpophalangeal Joint Arthroplasty in Rheumatoid Arthritis. <i>Plastic and Reconstructive Surgery</i> , 2013, 132, 597-603.	0.7	9
76	Interleukin-5 Supports the Expansion of Fas Ligand-Expressing Killer B Cells that Induce Antigen-Specific Apoptosis of CD4+ T Cells and Secrete Interleukin-10. <i>PLoS ONE</i> , 2013, 8, e70131.	1.1	39
77	Regulation of Th17 Maturation by Interleukin 4. <i>Critical Reviews in Immunology</i> , 2013, 33, 379-387.	1.0	7
78	The roles of IFN- γ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. <i>Modern Rheumatology</i> , 2013, 23, 1140-50.	0.9	22
79	Reflecting on Early Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 2059-2061.	1.0	5
80	Long-term followup for rheumatoid arthritis patients in a multicenter outcomes study of silicone metacarpophalangeal joint arthroplasty. <i>Arthritis Care and Research</i> , 2012, 64, 1292-1300.	1.5	45
81	Kinase Inhibition – A New Approach to the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 565-567.	13.9	27
82	Treg cells to the rescue. <i>Arthritis and Rheumatism</i> , 2012, 64, 2426-2428.	6.7	0
83	Divergence of the systemic immune response following oral infection with distinct strains of <i>Porphyromonas gingivalis</i> . <i>Molecular Oral Microbiology</i> , 2012, , n/a-n/a.	1.3	0
84	Historical Perspective on the Etiology of Rheumatoid Arthritis. <i>Hand Clinics</i> , 2011, 27, 1-10.	0.4	63
85	Advances in the Medical Treatment of Rheumatoid Arthritis. <i>Hand Clinics</i> , 2011, 27, 11-20.	0.4	138
86	A polymorphism in the interleukin-4 receptor affects the ability of interleukin-4 to regulate Th17 cells: a possible immunoregulatory mechanism for genetic control of the severity of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R15.	1.6	24
87	Sensitivity and Resistance to Regulation by IL-4 during Th17 Maturation. <i>Journal of Immunology</i> , 2011, 187, 4440-4450.	0.4	68
88	Differences between the United States and the United Kingdom in the treatment of rheumatoid arthritis: analyses from a hand arthroplasty trial. <i>Clinical Rheumatology</i> , 2010, 29, 363-367.	1.0	8
89	Co-stimulation and T cells as therapeutic targets. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 463-477.	1.4	19
90	Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?. <i>Clinical and Translational Science</i> , 2010, 3, 319-326.	1.5	23

#	ARTICLE	IF	CITATIONS
91	Validity and responsiveness of the Michigan hand questionnaire in patients with rheumatoid arthritis: A multicenter, international study. <i>Arthritis Care and Research</i> , 2010, 62, 1569-1577.	1.5	74
92	Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: Effect of angiotensin receptor blockers. <i>Arthritis and Rheumatism</i> , 2010, 62, 1319-1328.	6.7	49
93	The role of T helper type 17 cells in inflammatory arthritis. <i>Clinical and Experimental Immunology</i> , 2010, 159, 225-237.	1.1	75
94	Membrane-Type I Matrix Metalloproteinase-Dependent Regulation of Rheumatoid Arthritis Synoviocyte Function. <i>Journal of Immunology</i> , 2010, 184, 6396-6406.	0.4	87
95	Preface. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, xiii-xiv.	0.8	0
96	Cell-cell Interactions in Rheumatoid Arthritis Synovium. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 311-323.	0.8	66
97	Targeting IL-17 and Th17 Cells in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 345-366.	0.8	71
98	Unity in the field of rheumatology: The role of the ACR. <i>Arthritis and Rheumatism</i> , 2009, 60, 313-316.	6.7	1
99	The future of ILAR. <i>Clinical Rheumatology</i> , 2009, 28, 493-494.	1.0	0
100	A Multicenter Clinical Trial in Rheumatoid Arthritis Comparing Silicone Metacarpophalangeal Joint Arthroplasty With Medical Treatment. <i>Journal of Hand Surgery</i> , 2009, 34, 815-823.	0.7	70
101	Outcomes of Silicone Arthroplasty for Rheumatoid Metacarpophalangeal Joints Stratified by Fingers. <i>Journal of Hand Surgery</i> , 2009, 34, 1647-1652.	0.7	36
102	Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. <i>Arthritis Research and Therapy</i> , 2009, 11, R158.	1.6	76
103	Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, R128.	1.6	78
104	A Prospective Study Comparing Outcomes after Reconstruction in Rheumatoid Arthritis Patients with Severe Ulnar Drift Deformities. <i>Plastic and Reconstructive Surgery</i> , 2009, 123, 1769-1777.	0.7	27
105	Regulatory T cells in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2008, 10, 405-412.	2.1	10
106	The past and the future of Arthritis & Rheumatism: A view from the American College of Rheumatology. <i>Arthritis and Rheumatism</i> , 2008, 58, S7-S10.	6.7	0
107	Th17 cells in human disease. <i>Immunological Reviews</i> , 2008, 223, 87-113.	2.8	960
108	High-Throughput Profiling of Ion Channel Activity in Primary Human Lymphocytes. <i>Analytical Chemistry</i> , 2008, 80, 3728-3735.	3.2	22

#	ARTICLE	IF	CITATIONS
109	Crystal Structure of the BARD1 Ankyrin Repeat Domain and Its Functional Consequences. <i>Journal of Biological Chemistry</i> , 2008, 283, 21179-21186.	1.6	35
110	Interactions of T Cells with Fibroblast-Like Synoviocytes: Role of the B7 Family Costimulatory Ligand B7-H3. <i>Journal of Immunology</i> , 2008, 180, 2989-2998.	0.4	62
111	CD19+CD5+ B Cells in Primary IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 2130-2139.	3.0	36
112	Etanercept-associated Pulmonary Granulomatous Inflammation in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 2279.2-2282.	1.0	25
113	Molecular Interactions between T Cells and Fibroblast-Like Synoviocytes. <i>American Journal of Pathology</i> , 2007, 171, 1588-1598.	1.9	62
114	Cells of the synovium in rheumatoid arthritis. T lymphocytes. <i>Arthritis Research and Therapy</i> , 2007, 9, 202.	1.6	191
115	Interleukin-17 as a molecular target in immune-mediated arthritis: Immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. <i>Arthritis and Rheumatism</i> , 2007, 56, 89-100.	6.7	48
116	Regulatory T cell defects in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 710-713.	6.7	43
117	Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. <i>Arthritis and Rheumatism</i> , 2007, 56, 1497-1506.	6.7	88
118	Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1827-1835.	6.7	64
119	Endothelial dysfunction in rat adjuvant-induced arthritis: Vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase. <i>Arthritis and Rheumatism</i> , 2006, 54, 1847-1855.	6.7	73
120	Treatment for Rheumatic Disorders. <i>New England Journal of Medicine</i> , 2006, 354, 1322-1323.	13.9	0
121	Immunocompetent Properties of Human Osteoblasts: Interactions With T Lymphocytes. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 29-36.	3.1	58
122	Cytokine production by dendritic cells genetically engineered to express IL-4: induction of Th2 responses and differential regulation of IL-12 and IL-23 synthesis. <i>Journal of Gene Medicine</i> , 2005, 7, 869-877.	1.4	15
123	Synovial biology and T cells in rheumatoid arthritis. <i>Pathophysiology</i> , 2005, 12, 183-189.	1.0	116
124	Expression and Characterization of a Novel CD6 Ligand in Cells Derived from Joint and Epithelial Tissues. <i>Journal of Immunology</i> , 2004, 173, 6125-6133.	0.4	36
125	Xenogeneic cells and superantigen induce human T-cell activation in the absence of T-cell recognition of xenoantigen. <i>Translational Research</i> , 2003, 142, 149-157.	2.4	1
126	Effectiveness of rheumatoid hand surgery: Contrasting perceptions of hand surgeons and rheumatologists. <i>Journal of Hand Surgery</i> , 2003, 28, 3-11.	0.7	98

#	ARTICLE	IF	CITATIONS
127	Surgical management of the rheumatoid hand: consensus and controversy among rheumatologists and hand surgeons. <i>Journal of Rheumatology</i> , 2003, 30, 1464-72.	1.0	41
128	CD6: expression during development, apoptosis and selection of human and mouse thymocytes. <i>International Immunology</i> , 2002, 14, 585-597.	1.8	56
129	The functional interactions between CD98, β 1-integrins, and CD147 in the induction of U937 homotypic aggregation. <i>Blood</i> , 2001, 98, 374-382.	0.6	119
130	Effector Function of Resting T Cells: Activation of Synovial Fibroblasts. <i>Journal of Immunology</i> , 2001, 166, 2270-2275.	0.4	102
131	Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. <i>Journal of Clinical Investigation</i> , 2001, 107, 1275-1284.	3.9	180
132	Evidence for the expression of a second CD6 ligand by synovial fibroblasts. <i>Arthritis and Rheumatism</i> , 2000, 43, 329.	6.7	22
133	Novel molecular mechanisms of dendritic cell-induced T cell activation. <i>International Immunology</i> , 2000, 12, 1051-1061.	1.8	50
134	Cytokine Blockade as a New Strategy to Treat Rheumatoid Arthritis. <i>Archives of Internal Medicine</i> , 2000, 160, 437.	4.3	66
135	Interactions between T cells and synovial fibroblasts. <i>Modern Rheumatology</i> , 2000, 10, 16-18.	0.9	3
136	Systemic Toxicity Following Administration of Sirolimus (Formerly Rapamycin) for Psoriasis. <i>Archives of Dermatology</i> , 1999, 135, 553-7.	1.7	49
137	Rheumatoid Arthritis—Heresies and Speculations. <i>Perspectives in Biology and Medicine</i> , 1997, 40, 479-491.	0.3	6
138	CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on β 3-interferon activated keratinocytes. <i>Immunology Letters</i> , 1997, 58, 9-14.	1.1	22
139	The role of T cells in the immunopathogenesis of rheumatoid arthritis. New perspectives. <i>Arthritis and Rheumatism</i> , 1997, 40, 598-609.	6.7	269
140	Mouse CD6: sequence of cDNA and expression of mRNA. <i>Immunology Letters</i> , 1996, 49, 133-137.	1.1	3
141	Responsiveness of human T lymphocytes to bacterial superantigens presented by cultured rheumatoid arthritis synoviocytes. <i>Arthritis and Rheumatism</i> , 1996, 39, 125-136.	6.7	62
142	Biological therapies: A novel approach to the treatment of autoimmune disease. <i>American Journal of Medicine</i> , 1995, 99, 82-88.	0.6	27
143	Immediate hypersensitivity reaction to cyclophosphamide. <i>Arthritis and Rheumatism</i> , 1994, 37, 1101-1104.	6.7	16
144	The Human 4F2 Antigen: Evidence for Cryptic and Noncryptic Epitopes and for a Role of 4F2 in Human T Lymphocyte Activation. <i>Cellular Immunology</i> , 1994, 154, 253-263.	1.4	24

#	ARTICLE	IF	CITATIONS
145	Effects of administration of an anti-cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies. <i>Arthritis and Rheumatism</i> , 1993, 36, 620-630.	6.7	86
146	T-Lymphocyte Clones Initiated from Lesional Psoriatic Skin Release Growth Factors that Induce Keratinocyte Proliferation. <i>Journal of Investigative Dermatology</i> , 1993, 101, 695-700.	0.3	86
147	Leukemic T Cells from Patients with Cutaneous T-Cell Lymphoma Demonstrate Enhanced Activation Through CDw60, CD2, and CD28 Relative to Activation Through the T-Cell Antigen Receptor Complex. <i>Journal of Investigative Dermatology</i> , 1993, 100, 667-673.	0.3	28
148	An Anti-CD2 Monoclonal Antibody That Both Inhibits and Stimulates T Cell Activation Recognizes a Subregion of CD2 Distinct from Known Ligand-Binding Sites. <i>Cellular Immunology</i> , 1993, 150, 235-246.	1.4	11
149	Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. <i>International Immunology</i> , 1993, 5, 783-792.	1.8	61
150	Cell cycle progression is associated with distinct patterns of phosphorylation of Op18. <i>Biochemical and Biophysical Research Communications</i> , 1992, 185, 197-203.	1.0	35
151	Fine Mapping of Monoclonal Antibody Epitopes on Human von Willebrand Factor Using a Recombinant Peptide Library. <i>Thrombosis and Haemostasis</i> , 1992, 67, 166-171.	1.8	17
152	Defective CD2 pathway T cell activation in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1991, 34, 561-571.	6.7	28
153	UM4D4+ (CDw60) T Cells Are Compartmentalized into Psoriatic Skin and Release Lymphokines That Induce a Keratinocyte Phenotype Expressed in Psoriatic Lesions. <i>Journal of Investigative Dermatology</i> , 1990, 95, 275-282.	0.3	91
154	Activation of human T cell clones through the UM4D4/CDw60 surface antigen. <i>Cellular Immunology</i> , 1990, 128, 480-489.	1.4	10
155	Abnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseases. <i>American Journal of Medicine</i> , 1988, 84, 817-825.	0.6	84
156	Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 1988, 318, 1423-1431.	13.9	288
157	Secondary immune amplification following live poliovirus immunization in humans. <i>Clinical Immunology and Immunopathology</i> , 1987, 44, 321-328.	2.1	11
158	In Vivo Activated T Lymphocytes in the Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple Sclerosis. <i>New England Journal of Medicine</i> , 1985, 312, 1405-1411.	13.9	310
159	Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 1985, 312, 818-822.	13.9	833
160	An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor protein. <i>Cell</i> , 1984, 36, 897-906.	13.5	1,153